{
    "clinical_study": {
        "@rank": "109109", 
        "acronym": "rhFVIIa", 
        "arm_group": [
            {
                "arm_group_label": "Cohort 1", 
                "arm_group_type": "Experimental", 
                "description": "10 patients administered a single low dose of rhFVIIa"
            }, 
            {
                "arm_group_label": "Cohort 2", 
                "arm_group_type": "Experimental", 
                "description": "10 patients administered a single intermediate dose of rhFVIIa"
            }, 
            {
                "arm_group_label": "Cohort 3", 
                "arm_group_type": "Experimental", 
                "description": "10 patients administered a single high dose of rhFVIIa"
            }
        ], 
        "brief_summary": {
            "textblock": "This study will assess the pharmacokinetics and pharmacodynamics of rhFVIIa at three dose\n      levels. The results will help identify the most optimal doses to take forward to the Phase\n      2/3 studies where bleedings in hemophilia patients with inhibitors will be treated with\n      rhFVIIa."
        }, 
        "brief_title": "A Phase I Safety, Pharmacokinetics and Pharmacodynamics Study of Recombinant Factor VIIa in Adult Patients With Hemophilia A or B", 
        "completion_date": {
            "#text": "June 2013", 
            "@type": "Actual"
        }, 
        "condition": "Hemophilia", 
        "condition_browse": {
            "mesh_term": "Hemophilia A"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. be male with a diagnosis of moderate or severe congenital hemophilia A  and/or B\n             (with or without inhibitors)\n\n          2. be 18 years or older, up to and including 75 years of age\n\n          3. be capable of understanding and willing to comply with the conditions of the protocol\n\n          4. have read, understood and provided written informed consent\n\n        Exclusion Criteria:\n\n          1. have any coagulation disorder other than hemophilia A or B\n\n          2. have a body weight >105 kg (231 lb)\n\n          3. be immuno-suppressed (i.e., the patient should not receive systemic immunosuppressive\n             medication <30 days prior to enrollment, CD4 counts at screening should be >200/\u00b5l)\n\n          4. have a known allergy or hypersensitivity to rabbits\n\n          5. have platelet count <100,000/mL\n\n          6. have had within one month prior to first administration of the study drug in this\n             study a major surgical procedure (e.g. orthopedic, abdominal)\n\n          7. have an active, ongoing bleeding for which the patient is being treated, or treatment\n             for a bleeding was stopped within 24 hours of the time of study drug administration\n\n          8. have received a Factor VII or FVIIa containing product (either plasma derived or\n             recombinant) within 72 hours prior to any study drug administration\n\n          9. have received an investigational drug within 30 days of the first study drug\n             administration, or is expected to receive such drug during participation in this\n             study\n\n         10. have a clinically relevant hepatic (hepatic enzymes >3 times the upper limit of\n             normal) and/or renal impairment (creatinine >2 times the upper limit of normal)\n\n         11. have a history of arterial and/or venous thromboembolic events (such as myocardial\n             infarction, ischemic strokes, transient ischemic attacks, deep venous thrombosis or\n             pulmonary embolism) within 2 years prior to first dose of study drug, have an\n             arterial stent in place or have clinically significant atherosclerotic disease (e.g.,\n             angina pectoris, peripheral vascular disease)\n\n         12. use any anticoagulant for arterial/venous obstructions and/or atrial fibrillation\n             within 7 days prior to first study drug administration\n\n         13. have an active malignancy (those with non-melanoma skin cancer are allowed)\n\n         14. have any life-threatening disease or other disease or condition which, according to\n             the investigator's judgment, could imply a potential hazard to the patient, interfere\n             with the trial participation or trial outcome"
            }, 
            "gender": "Male", 
            "healthy_volunteers": "No", 
            "maximum_age": "75 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "15", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "October 15, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01708564", 
            "org_study_id": "GTC-FVIIa-005-11", 
            "secondary_id": "2012-002285-13"
        }, 
        "intervention": {
            "arm_group_label": [
                "Cohort 1", 
                "Cohort 2", 
                "Cohort 3"
            ], 
            "description": "Patients will be administered low, intermediate and high doses of rhFVIIa", 
            "intervention_name": "rhFVIIa", 
            "intervention_type": "Biological", 
            "other_name": "Coagulation Factor VIIa (Recombinant)"
        }, 
        "intervention_browse": {
            "mesh_term": "Factor VIII"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "July 29, 2013", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Sacramento", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "95817"
                    }, 
                    "name": "UC Davis Health System Internal Medicine: Hematology & Oncology"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Chicago", 
                        "country": "United States", 
                        "state": "Illinois", 
                        "zip": "60612"
                    }, 
                    "name": "RUSH Hemophilia & Thrombophilia Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Leiden", 
                        "country": "Netherlands"
                    }, 
                    "name": "Centre for Human Drug Research"
                }
            }
        ], 
        "location_countries": {
            "country": [
                "United States", 
                "Netherlands"
            ]
        }, 
        "number_of_arms": "3", 
        "official_title": "A Phase 1b, Dose Escalation Study to Assess the Safety, Pharmacokinetics and Pharmacodynamics of Coagulation Factor VIIa (Recombinant) in Congenital Hemophilia A or B Patients", 
        "overall_official": {
            "affiliation": "rEVO Biologics", 
            "last_name": "Johan Frieling, MD,PhD", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": [
                "United States: Food and Drug Administration", 
                "Netherlands: The Central Committee on Research Involving Human Subjects (CCMO)"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "June 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Factor VIIa concentration in patient plasma as measured by FVIIa PK and PD assays", 
            "safety_issue": "No", 
            "time_frame": "Up to 36 hours of dosing"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01708564"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "Incidence of patients with treatment emergent adverse events", 
            "safety_issue": "Yes", 
            "time_frame": "Up to 28 days after dosing"
        }, 
        "source": "rEVO Biologics", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "rEVO Biologics", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "October 2012", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science", 
        "study_type": "Interventional", 
        "verification_date": "July 2013"
    }
}